Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Similar articles for PubMed (Select 19765253)


Does cinacalcet improve the prognosis of dialysis patients?

Taniguchi M, Yamada S, Tokumoto M, Tsuruya K, Hirakata H, Fujimi S, Iida M.

Ther Apher Dial. 2009 Oct;13 Suppl 1:S15-9. doi: 10.1111/j.1744-9987.2009.00770.x.


Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.

Wilkie M, Pontoriero G, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Zani VJ, Carter D, Messa P.

Nephron Clin Pract. 2009;112(1):c41-50. doi: 10.1159/000212102. Epub 2009 Apr 10.


Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.

Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW.

J Am Soc Nephrol. 2005 Mar;16(3):800-7. Epub 2005 Feb 2.


Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl.

Sprague SM, Evenepoel P, Curzi MP, González MT, Husserl FE, Kopyt N, Sterling LR, Mix C, Wong G.

Clin J Am Soc Nephrol. 2009 Sep;4(9):1465-76. doi: 10.2215/CJN.06141108. Epub 2009 Aug 20.


Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.

Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, Ling X, Goodman WG, Turner S, Charytan C.

Clin J Am Soc Nephrol. 2008 Nov;3(6):1718-25. doi: 10.2215/CJN.01040308.


Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.

Ureña-Torres P, Bridges I, Christiano C, Cournoyer SH, Cooper K, Farouk M, Kopyt NP, Rodriguez M, Zehnder D, Covic A.

Nephrol Dial Transplant. 2013 May;28(5):1241-54. doi: 10.1093/ndt/gfs568. Epub 2013 Jan 16.


[German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY)].

Reichel H, Braun J.

Dtsch Med Wochenschr. 2011 Jan;136(4):123-8. doi: 10.1055/s-0030-1247876. Epub 2010 Dec 21. German.


Clinical issues regarding cinacalcet hydrochloride in Japan.

Yokoyama K.

Ther Apher Dial. 2009 Oct;13 Suppl 1:S12-4. doi: 10.1111/j.1744-9987.2009.00769.x.


Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.

Frazão JM, Messa P, Mellotte GJ, Geiger H, Hagen EC, Quarles LD, Kerr PG, Baños A, Dehmel B, Urena P.

Clin Nephrol. 2011 Sep;76(3):233-43.


The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.

Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J; ADVANCE Study Group.

Nephrol Dial Transplant. 2011 Apr;26(4):1327-39. doi: 10.1093/ndt/gfq725. Epub 2010 Dec 8.


The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Mealing S, Roome C, Snaith A, D'Souza R, Welch K, Stein K.

Health Technol Assess. 2007 May;11(18):iii, xi-xiii, 1-167. Review.


Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.

Charytan C, Coburn JW, Chonchol M, Herman J, Lien YH, Liu W, Klassen PS, McCary LC, Pichette V.

Am J Kidney Dis. 2005 Jul;46(1):58-67.


Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism.

Yajima A, Akizawa T, Tsukamoto Y, Kurihara S, Ito A; K Study Group.

Ther Apher Dial. 2008 Oct;12 Suppl 1:S38-43. doi: 10.1111/j.1744-9987.2008.00630.x.


Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.

Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, Bushinsky DA; TARGET Investigators.

Nephrol Dial Transplant. 2008 Jul;23(7):2311-8. doi: 10.1093/ndt/gfn026. Epub 2008 Feb 29.


Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism.

Akiba T, Akizawa T, Tsukamoto Y, Uchida E, Iwasaki M, Koshikawa S; KRN1493 Study Group.

Ther Apher Dial. 2008 Apr;12(2):117-25. doi: 10.1111/j.1744-9987.2008.00556.x.


Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.

Arenas MD, Alvarez-Ude F, Gil MT, Moledous A, Malek T, Nuñez C, Devesa R, Carretón MA, Soriano A.

Nephrol Dial Transplant. 2007 Jun;22(6):1639-44. Epub 2007 Feb 3.


Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy.

Eandi M, Pradelli L, Iannazzo S, Chiroli S, Pontoriero G.

Pharmacoeconomics. 2010;28(11):1041-54. doi: 10.2165/11538600-000000000-00000.


Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.

Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M.

Nephrol Dial Transplant. 2012 Feb;27(2):784-90. doi: 10.1093/ndt/gfr384. Epub 2011 Jul 5.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk